Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Retained Earnings (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Retained Earnings for 4 consecutive years, with $45000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 100.02% to $45000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $45000.0, a 100.02% increase, with the full-year FY2024 number at $52000.0, up 620.0% from a year prior.
  • Retained Earnings was $45000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $16000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $52000.0 in Q4 2024 to a low of -$328.6 million in Q1 2025.
  • A 4-year average of -$60.0 million and a median of -$77000.0 in 2023 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 620.0% in 2024; the steepest drop was 749377.14% in 2024.
  • Orchestra BioMed Holdings' Retained Earnings stood at -$8000.0 in 2022, then dropped by 25.0% to -$10000.0 in 2023, then soared by 620.0% to $52000.0 in 2024, then fell by 13.46% to $45000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Retained Earnings are $45000.0 (Q3 2025), $16000.0 (Q2 2025), and -$328.6 million (Q1 2025).